Alnylam Pharmaceuticals, Inc Aktie News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, ww...

Many investors love the "big mo." That's short for "big momentum.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This year's edition...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Society of Cardi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The l...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the Company's websi...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants Tazeen Ahmad – Bank o...